Trial Profile
A Phase 2 Trial to Evaluate the Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jun 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Vicriviroc (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 17 Jun 2021 Status changed from active, no longer recruiting to completed.
- 19 Feb 2020 Planned End Date changed from 13 May 2020 to 10 Jun 2021.
- 19 Feb 2020 Planned primary completion date changed from 13 May 2020 to 10 Jun 2021.